Queens
Astoria
37-15 23rd Ave, Astoria, NY 11105
A western Queens option for patients who want easier access than crossing into Manhattan for every monitored treatment day.
View location detailsTreatment comparison
Spravato and ketamine are not the same treatment pathway. Spravato is FDA-approved esketamine nasal spray administered in a certified healthcare setting with monitoring, while ketamine treatment for psychiatric conditions is typically off-label.
Multi-location Spravato access across NYC and Long Island, with care-manager support, Medicaid access, and clinic options that account for repeated monitored visits.
Spravato is esketamine nasal spray and is available only through a restricted REMS program. It is administered under direct healthcare-provider supervision, with post-dose monitoring in a certified healthcare setting. It is not dispensed directly to patients for home use.
Ketamine may be used off-label by some practices for psychiatric conditions, often through IV, intramuscular, oral, or compounded formulations. The FDA has warned about potential risks with compounded ketamine products, including concerns when they are used outside a monitored healthcare setting.
Nao Medical focuses on REMS-certified Spravato care for eligible adults across NYC and Long Island.
Clinical references reviewed: SPRAVATO REMS and the FDA prescribing information. Last reviewed May 2026. This information does not replace a clinical evaluation.
Queens
37-15 23rd Ave, Astoria, NY 11105
A western Queens option for patients who want easier access than crossing into Manhattan for every monitored treatment day.
View location detailsBronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for patients who want local Spravato care without leaving the borough.
View location detailsLong Island
232 W Old Country Rd, Hicksville, NY 11801
A central Nassau option for patients who need consistent follow-up, prior auth support, and a shorter commute.
View location detailsQueens
90-18 Sutphin Blvd, Jamaica, NY 11435
A southeast Queens location that helps patients stay on schedule for repeated monitored sessions.
View location detailsQueens
30-07 36th Ave, Astoria, NY 11106
A western Queens access point for patients balancing treatment days with work, home, or Manhattan commutes.
View location detailsLong Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for patients who want strong benefits support and reliable treatment coordination.
View location detailsManhattan
259 1st Ave, New York, NY 10003
A Manhattan Spravato access point for East Village, Gramercy, Kips Bay, and nearby neighborhoods.
View location detailsBrooklyn
308 Graham Ave, Brooklyn, NY 11211
The lead Brooklyn Spravato location for patients who want local access and ongoing psychiatric support.
View location detailsAccepted plans can vary by eligibility and authorization rules. This list reflects the insurance access Nao Medical can review for eligible Spravato patients, including Medicaid, Medicare, Medicare Advantage, and commercial coverage options.
No. Spravato is esketamine nasal spray with FDA-approved indications and REMS requirements. IV ketamine for depression is a different, often off-label pathway.
No. Spravato must be administered in a certified healthcare setting with monitoring after dosing.
Many plans have defined coverage criteria for Spravato when requirements are met. Coverage still depends on benefits, diagnosis, and authorization.
Yes. Nao Medical evaluates eligible adults for Spravato and reviews insurance, Medicaid, monitoring, and scheduling requirements.